Screener
Nurix Therapeutics, Inc. NRIX NX-1607 — R&D
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.
- Filed
- Jul 9, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001549595-26-000040
| Line item | Three Months Ended May 31, 2026 | Three Months Ended May 31, 2025 | Six Months Ended May 31, 2026 | Six Months Ended May 31, 2025 |
|---|---|---|---|---|
| External clinical development expenses: | ||||
| Bexobrutideg (NX-5948) | $28,192 | $18,558 | $52,166 | $34,278 |
| Zelebrudomide (NX-2127) | 1,167 | 1,559 | 3,073 | 2,665 |
| NX-1607 | 1,738 | 2,332 | 2,926 | 4,292 |
| Internal research and development expenses | 56,556 | 55,647 | 113,624 | 106,524 |
| Total research and development expenses | $87,653 | $78,096 | $171,789 | $147,759 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Nurix Therapeutics, Inc.'s NX-1607 — R&D?
- Nurix Therapeutics, Inc. (NRIX) reported NX-1607 — R&D of $1.74M in Q1 2026.
- How has Nurix Therapeutics, Inc.'s NX-1607 — R&D changed year-over-year?
- Nurix Therapeutics, Inc.'s NX-1607 — R&D decreased by 25.5% year-over-year, from $2.33M to $1.74M.
- What does NX-1607 — R&D mean?
- This metric represents the direct operating expenses allocated to the research and development of a specific clinical-stage therapeutic candidate. It captures the investment in preclinical studies, clinical trials, and manufacturing process development required to advance this specific asset toward regulatory approval. Monitoring this spend provides insight into the company's capital allocation strategy and the prioritization of its pipeline assets.
Ask your AI about Nurix Therapeutics, Inc.'s nx-1607 — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude